Early research (Phase 1)Study completedNCT03515512
What this trial is testing
IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
Who this might be right for
Acute Myeloid LeukemiaChronic Myelomonocytic Leukemia
Massachusetts General Hospital 23